Medical cycle times are often long and painful, but they realise a significant payday when a new technology emerges. In the United States, medical OEMs strive to develop scientific breakthroughs that first receive 510 Federal Drug Administration clearance in order to market and start a revenue stream. Since this process can take one to two years, JLM concentrates its efforts with European OEMs (with revenue of $50M+) that want to enter the US market. In these cases, we obtain a license agreement with an OEM that have an establish customer base.

Also cover medical devices that have market acceptance on the human side and develop the animal health market.

companies under agreement:


Soft-Ox Solutions AS

Oslo, Norway

SoftOx Solutions AS Advanced Hard -to Heal Wound Treatment As Supplement to Antibiotics For Animal Healthcare

SoftOx Solutions AS is a Norwegian MedTech company listed on Oslo Stock Exchange – Mercur Market – with HQ in Oslo and with a subsidiary in Copenhagen. SoftOx is developing solutions for wound treatment, partly to prevent infections, partly to fight hard- to-heal wounds / chronic wounds where biofilm is present and part of the problem.In cooperation with leading specialist on biofilm, SoftOx has developed a technology that enables us to produce a stable and effective solution by combining known antimicrobial substances in a way no one has done before.

The first firm to stabilise Hyochlorous Acid plus add Acetic Acid providing a unique synergy which provides broad- spectrum towards bacteria , moulds viruses and spores. Soft-OX are engage with wound care firms with a base NOT hyochlorous acid as Soft-Ox is just review as competition.

As the severity of antibiotic resistance gradually is acknowledged, SoftOx sees a huge a market potential for our products.

Our products are protected by a large patent family

  • SoftOx products are intended for humans as well as for animals.

  • Fighting antibiotic resistance is a cornerstone in our vision and SoftOx therefore aims at playing a significant role in prevention against, and treatment of hard-to heal wounds as a supplement to antibiotics.

As the severity of antibiotic resistance gradually is acknowledged, SoftOx sees a huge a market potential for our products.

Soft-OX Joint Venture Overview

Softox presentation


Decon-X International AS Vollsveien 13C, 1366 Lysaker, Norway

Decon-X are focusing on chemistries firms with a hydrogen peroxide base formulation and have strong customer based in animal healthcare. Also certified peroxide regulatory registration expertise with EPA as need experience working on this platform. The intelligent system will control the solution usage and provide higher efficiency. Annual cost will be less and much better control.Decon-X system can be added to your product line as automate system no manual labor required.

Automated disinfection systems for rooms and equipment:

  • Approved for use in health institutions and on food production equipment

  • Disinfects the whole room and all equipment inside

  • Currently in Vet hospitals in Europe including MAR’s Anicura Animal Hospital

  • Documented 6 log10 disinfection

  • A high kill rate is require when outbreak occurs

  • Avoid outbreaks like Parvo virus is only common between cats and dogs with automation system with high kill rate

  • Horses have an outbreak called "Kverke" it hits the lungs of the horses which can be removal by Decon-X

  • Cats Feline Calicivirus belongs to the family Caliciviridea

  • Enclose ( above ) is a specific study on Feline Calicivirus from the University of Lund in Sweden has been published,

  • Decon-X validate our process using "bacterial endospores", ie Geobacillus stearothermophilus, the most robust organism in the world, and demonstrate that Decon-X kill this 100%.

    Thereby we also prove that microorganisms less robust than Geobacillus stearothermophilus, ie dying out faster than this, are also killed and this includes Feline Calcivirus.

    Researches conclude that no viable viruses can be detected after the disinfection process and that a successful inactivation has been achieved, which in everyday speaking means that 100% of the viruses has been killed.

    So a disinfection using dry mist hydrogen peroxide will a be a very effective means of removing Feline Calicivirus from the environment in animal hospitals.

  • Automated reporting

animal health with statements

DX technology

microbial hierarchy



JLM client Dualis brings in ReliantHeart

Dualis MedTech and ReliantHeart Partner on Fully Implantable TET System for the HeartAssist5® LVAD

ReliantHeart, Inc., an innovative supplier of advanced mechanical circulatory assist technologies, and Dualis MedTech GmbH, a provider of wireless energy and charging technology, have joined together to implement a wireless, Transcutaneous Energy Transfer system (TET) exclusively for the HeartAssist5® Ventricular Assist Device.

Dualis has agreed to integrate its wireless energy transfer technology MedBase® with the HeartAssist5® VAD.  ReliantHeart’s novel HeartAssist5® (HA5) is the most energy efficient LVAD available.

In its new configuration, the HA5 will draw less than half of the energy of any other full flow LVAD. ReliantHeart refers to this energy efficient pump as being Forward Compatible with future product introduction, including the wireless Transcutaneous Energy Transfer system (TET).

Dualis is an integral part of a Forward Compatibility team formed by ReliantHeart to cooperate on an assembly of technologies intended to reduce adverse events associated with LVADs. The team includes several other companies: Lynium, Kollmorgen, Device Solutions, Transonic, Revel Engineering, Numerex, Cathtek, and Yarborough Electronics.

Several months of collaboration culminated in Houston last month, where engineers and product managers from these companies shared a behind-the-scenes tour of the Johnson Space Center, an appropriate setting for both Dualis and ReliantHeart whose roots stem from the aerospace industry.   Dualis was formed from the German Centre for Aeronautics and Aerospace, and now implements its technologies for the medical device industry. ReliantHeart’s ventricular pump was developed with NASA technology and was awarded the NASA Invention of the Year.

According to ReliantHeart CEO Rodger Ford; “Dualis is heads and shoulders above most similar teams of its kind. Our partnership is more than just collaboration, it is a crusade to reduce adverse events in the LVAD field. Our mission is to compress time and accelerate beneficial outcomes.  Artificial heart pumps need power but running wires through the skin leads to infection and patient discomfort. The solution is to invent a device to transfer power without wires.”

Dualis MedBase® technology will provide this solution by using magnetic coils to transfer power from outside to inside the body with no wires that penetrate the body. It sounds like science fiction, and yet will be available in 2016. Patients with a ReliantHeart HA5 will be able to upgrade to the wireless system without exchanging the pump, thereby eliminating driveline infection. “Patients will be able to enjoy the physical and social activities that are limitless without a wire,” Ford said.

Dualis MedTech GmbH started research and development of the MedBase® technology in 2006 and has since gained a substantial lead in wireless power technology, and conducted successful animal trials. Stephan Sagolla, CEO of Dualis indicated, “The internal coil is about two inches in diameter and will communicate with an internal battery and power management much like a pacemaker system. The patient will be wireless.”

ReliantHeart, Inc. is an innovative supplier of advanced mechanical circulatory assist technologies that are changing the approach to the treatment of advanced heart failure.  It develops and manufactures the HeartAssist5® Ventricular Assist Device.  ReliantHeart’s roots are in Houston, Texas, where it has been generously influenced by the transplant centers of Texas Heart, Methodist DeBakey and Memorial Hermann, and its technology originally inspired by NASA, the Johnson Space Center and Baylor School of Medicine.

Dualis MedTech GmbH is an innovative development service provider which supports its customers from the idea stage right through to the certification of tailor-made systems and products. As a spin-off of the Deutsches Zentrum für Luft- und Raumfahrt (DLR e. V., German Centre for Aeronautics and Aerospace), the company has transferred technology used in aeronautics and applied it to medical technology and also provide services to other sectors such as the automotive supply industry, consumer electronics and machine and plant construction.

Dualis offers manufacturers of medical devices and active implants a fully comprehensive service package for the production, integration and adjustment of MedBase® to their proprietary products. Dualis complies with the extremely demanding regulatory requirements for medical devices.